Mouse myeloma cell line NS0-derived recombinant human Complement Factor D Ile26-Ala253 Accession # P00746
Specificity
Detects human Complement Factor D in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant mouse Complement Factor D is observed, and less than 1% cross-reactivity with recombinant human (rh) Complement Factor B and rhComplement Factor I is observed.
Source
N/A
Isotype
IgG
Clonality
Polyclonal
Host
Goat
Gene
CFD
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Preservative
No Preservative
Concentration
LYOPH
Reconstitution Instructions
Reconstitute at 0.2 mg/mL in sterile PBS.
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Complement Factor D/Adipsin Antibody [Unconjugated]
Adipsin
ADN
ADNcomplement factor D
AMBP-1
C3 convertase activator
CFD
complement factor D (adipsin)
complement factor D preproprotein
Complement Factor D
D component of complement (adipsin)
DF
EC 3.4.21
EC 3.4.21.46
PFD
Properdin factor DADIPSIN
Background
Complement Factor D is a serine protease that catalyzes the initial proteolytic step in the alternative pathway of complement. Expressed in adipose tissue at high levels, factor D is also known as adipsin (1). It is an exceptionally specific protease and the only known protein substrate is factor B in complex with C3 (2). Factor D protease activity is regulated by reversible conformational changes, which differs from the majority of serine proteases whose regulation involves either activation by processing of the zymogens or inactivation by binding of the inhibitors. Compared to its physiologically important proteolytic activity, factor D has much lower activity toward synthetic peptide substrates. However, thioester substrates have been routinely used for assessing factor D activity (3).
White, R.T. et al. (1992) J. Biol. Chem. 267:9210.
Taylor, F.R. et al. (1999) Biochemistry 38:2849.
Kim, S. et al. (1995) J. Biol. Chem. 270:24399.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Reviews for Complement Factor D/Adipsin Antibody (AF1824) (0)
There are no reviews for Complement Factor D/Adipsin Antibody (AF1824).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
Bioinformatics Tool for Complement Factor D/Adipsin Antibody (AF1824)
Discover related pathways, diseases and genes to Complement Factor D/Adipsin Antibody (AF1824). Need help?
Read the Bioinformatics Tool Guide for instructions on using this tool.
Diseases for Complement Factor D/Adipsin Antibody (AF1824)
Discover more about diseases related to Complement Factor D/Adipsin Antibody (AF1824).
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our Complement Factor D/Adipsin Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.